Bettelheim P - Search Results

1

High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison.

Hiddemann W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Becker K, Balleisen L, Lathan B, et al. Hiddemann W, et al. Among authors: bettelheim p. Semin Hematol. 1991 Jul;28(3 Suppl 4):35-8. Semin Hematol. 1991. PMID: 1780750 Clinical Trial. No abstract available.

2

High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison.

Hiddemann W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Becker K, Balleisen L, Lathan B, et al. Hiddemann W, et al. Among authors: bettelheim p. Leuk Lymphoma. 1993;10 Suppl:133-7. doi: 10.3109/10428199309149125. Leuk Lymphoma. 1993. PMID: 8481662 Clinical Trial.

3

Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.

Kern W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Wörmann B, Büchner T, Hiddemann W. Kern W, et al. Among authors: bettelheim p. Leukemia. 1998 Jul;12(7):1049-55. doi: 10.1038/sj.leu.2401066. Leukemia. 1998. PMID: 9665189 Clinical Trial.

4

Transforming growth factor-beta 1 interferes with the proliferation-inducing activity of stem cell factor in myelogenous leukemia blasts through functional down-regulation of the c-kit proto-oncogene product.

de Vos S, Brach MA, Asano Y, Ludwig WD, Bettelheim P, Gruss HJ, Herrmann F. de Vos S, et al. Among authors: bettelheim p. Cancer Res. 1993 Aug 1;53(15):3638-42. Cancer Res. 1993. PMID: 7687925

5

Granulocyte colony-stimulating factor (G-CSF) as an adjunct to induction chemotherapy of adult acute lymphoblastic leukemia (ALL).

Scherrer R, Geissler K, Kyrle PA, Gisslinger H, Jäger U, Bettelheim P, Laczika K, Locker G, Scholten C, Sillaber C, et al. Scherrer R, et al. Among authors: bettelheim p. Ann Hematol. 1993 Jun;66(6):283-9. doi: 10.1007/BF01695970. Ann Hematol. 1993. PMID: 7686404

6

Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes.

Valent P, Hofmann WK, Büsche G, Sotlar K, Horny HP, Haase D, Haferlach T, Kern W, Bettelheim P, Baumgartner C, Sperr WR, Nösslinger T, Wimazal F, Giagounidis AA, Lübbert M, Krieger O, Kolb HJ, Stauder R, Pfeilstöcker M, Gattermann N, Fonatsch C, Aul C, Germing U. Valent P, et al. Among authors: bettelheim p. Ann Hematol. 2009 Jul;88(7):607-11. doi: 10.1007/s00277-008-0673-7. Epub 2009 Jan 16. Ann Hematol. 2009. PMID: 19148644

7

High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL)--a single-institution study.

Scherrer R, Bettelheim P, Geissler K, Jäger U, Knöbl P, Kyrle PA, Laczika K, Mitterbauer G, Neumann E, Schneider B, et al. Scherrer R, et al. Among authors: bettelheim p. Ann Hematol. 1994 Oct;69(4):181-8. doi: 10.1007/BF02215951. Ann Hematol. 1994. PMID: 7948304 Clinical Trial.

8

Hepatic and splenic abscesses--a common complication of intensive chemotherapy of acute myeloid leukemia (AML). A prospective study.

Grois N, Mostbeck G, Scherrer R, Chott A, Schwarzinger I, Muhm M, Bettelheim P, Forstinger C, Laczika K, Kyrle PA, et al. Grois N, et al. Among authors: bettelheim p. Ann Hematol. 1991 Jul;63(1):33-8. doi: 10.1007/BF01714958. Ann Hematol. 1991. PMID: 1878421

9

Coincidence of acquired factor-X deficiency and disseminated intravascular coagulation in patients with acute nonlymphoblastic leukemia.

Pabinger I, Bettelheim P, Dudczak R, Hinterberger W, Kyrle PA, Niessner H, Schwarzinger I, Speiser W, Lechner K. Pabinger I, et al. Among authors: bettelheim p. Ann Hematol. 1991 May;62(5):174-9. doi: 10.1007/BF01703144. Ann Hematol. 1991. PMID: 2049464

10

Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network.

Füreder W, Sperr WR, Heibl S, Zebisch A, Pfeilstöcker M, Stefanzl G, Jäger E, Greiner G, Schwarzinger I, Kundi M, Keil F, Hoermann G, Bettelheim P, Valent P. Füreder W, et al. Among authors: bettelheim p. Ann Hematol. 2020 Oct;99(10):2303-2313. doi: 10.1007/s00277-020-04214-z. Epub 2020 Aug 27. Ann Hematol. 2020. PMID: 32856141

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

160 results

Search Page

Filters